Gene
NF2
NF2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (19), Actionable biomarkers (44), Trial mentions (189), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention NF2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 4 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 5 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 6 of 8,738 | 0.07% | not measured | |
| 2025 | 9 of 8,875 | 0.10% | not measured | |
| 2024 | 12 of 8,597 | 0.14% | not measured | |
| 2023 | 8 of 8,275 | 0.10% | 8 of 11,460 | 0.07% |
| 2022 | 8 of 8,285 | 0.10% | 8 of 13,598 | 0.06% |
| 2021 | 7 of 8,692 | 0.08% | 27 of 15,045 | 0.18% |
| 2020 | 8 of 7,640 | 0.10% | 10 of 14,459 | 0.07% |
| 2019 | 5 of 7,300 | 0.07% | 13 of 12,159 | 0.11% |
| 2018 | 11 of 6,927 | 0.16% | 11 of 11,854 | 0.09% |
| 2017 | 10 of 6,558 | 0.15% | 4 of 11,595 | 0.03% |
Showing 10 of 37 years.
Assay-provider ledger (19)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Cell Signaling Technology | Reagent supplier | Clinical validation | 2 | December 01, 2025 |
| ROCHE DIAGNOSTICS | Context dependent | Clinical validation | 1 | December 01, 2025 |
| Illumina | Unclassified | Clinical validationAnalytical validation | 4 | June 21, 2025 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 1 | June 21, 2025 |
| Thermo Fisher | Reagent supplier | Clinical validationAnalytical validation | 2 | June 21, 2025 |
Showing 5 of 19 assay-provider companies.
Actionable biomarkers (44)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| NF2 oncogenic mutation | Chemotherapy | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| NF2 oncogenic mutation | Tensirolimus | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| NF2 deletion | Tensirolimus | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| NF2 deletion | Chemotherapy | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| NF2 deletion + EGFR oncogenic mutation | Erlotinib | responsive | lung carcinoma | Cancer Genome Interpreter |
Showing 5 of 44 actionable-biomarker assertions.
Trial mentions (189)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01024946 | Trial eligibility (AACT) |
| NCT04439331 | Trial eligibility (AACT) |
| NCT05684692 | Trial eligibility (AACT) |
| NCT07391150 | Trial eligibility (AACT) |
| NCT02934256 | Trial eligibility (AACT) |
Showing 5 of 189 trial mentions.
Target-disease associations (456)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| APC-related attenuated familial adenomatous polyposis | cancer or benign tumor | Mouse knockout (IMPC) |
| Acute Leukemia | cancer or benign tumor | Mouse knockout (IMPC) |
| Adrenal Gland Neuroblastoma | cancer or benign tumor | Cancer Gene Census |
| Anal Squamous Cell Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 456 associations.
Vendor sourcing (622)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. The variant is predicted to result in a loss or disruption of normal protein function through nonse... | View ClinVar record SCV004013622.1 |
| AHS Cancer Control Alberta | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : Boys and girls (n = 90) between 8 - 12 years of age with a sex- and age-specific BMI ≥95th percentile are eligible for this study. Children are referred to... | View trial NCT01267097 |
| AHS Cancer Control Alberta | Trial collaborator | Mentioned in trial textTrial free-text mention | SCH | View trial NCT01267097 |
| ALK-Abelló (Denmark) | Trial sponsor | Primary endpoint in a Phase 3 trialTrial endpoint | Number of Participants With Treatment-emergent Adverse Events (AEs) | View trial NCT01469182 |
| ALK-Abelló (Denmark) | Trial sponsor | Mentioned in trial textTrial free-text mention | SCH | View trial NCT01469182 |
Showing 5 of 622 sourcing records.
Trial-cited literature (149)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial. | Nature medicine | 2026 | 1 |
| Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study). | Trials | 2025 | 1 |
| Social support moderates quality of life outcomes during a mind-body intervention among adults with neurofibromatosis. | Journal of neuro-oncology | 2025 | 0 |
| Brigatinib in <i>NF2</i>-Related Schwannomatosis with Progressive Tumors. | The New England journal of medicine | 2024 | 60 |
| Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U. | JCO precision oncology | 2024 | 5 |
Showing 5 of 149 papers.
Protein variant mentions (69)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A13N | 1 | 2021 | PMID 34667843 |
| p.A199T | 1 | 2015 | PMID 25741868 |
| p.A238V | 1 | 2015 | PMID 25741868 |
| p.A2S | 1 | 2015 | PMID 25741868 |
| p.D277E | 1 | 2015 | PMID 25741868 |
Showing 5 of 69 variants.
Human sample screening reference (4)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.S288* | HCMI-CMDC | Ductal and Lobular Neoplasms; Complex Mixed and Stromal Neoplasms; Blood Vessel Tumors; Fibromatous Neoplasms; Epithelial Neoplasms, NOS; Mature T- and NK-Cell Lymphomas; Transitional Cell Papillomas and Carcinomas; Complex Epithelial Neoplasms; Squamous Cell Neoplasms; Soft Tissue Tumors and Sarcomas, NOS; Lymphoid Leukemias; Cystic, Mucinous and Serous Neoplasms; Gliomas; Myomatous Neoplasms; Neuroepitheliomatous Neoplasms; Malignant Lymphomas, NOS or Diffuse; Acinar Cell Neoplasms; Osseous and Chondromatous Neoplasms; Synovial-like Neoplasms; Miscellaneous Bone Tumors; Nevi and Melanomas; Adenomas and Adenocarcinomas; Other and unspecified parts of tongue; Stomach; Bronchus and lung; Larynx; Uterus, NOS; Kidney; Esophagus; Other and ill-defined sites; Skin; Colon; Thyroid gland; Bladder; Adrenal gland; Eye and adnexa; Gallbladder; Connective, subcutaneous and other soft tissues; Rectosigmoid junction; Breast; Pancreas; Small intestine; Corpus uteri; Other and unspecified parts of mouth; Liver and intrahepatic bile ducts; Nasal cavity and middle ear; Hematopoietic and reticuloendothelial systems; Brain; Other and unspecified parts of biliary tract; Bones, joints and articular cartilage of other and unspecified sites; Rectum; Unknown; Lymph nodes; Ovary | 1 | 606 | 0.17% | 0.03% to 0.93% |
| p.S288* | TCGA-HNSC | Squamous Cell Neoplasms; Base of tongue; Lip; Gum; Hypopharynx; Palate; Other and ill-defined sites in lip, oral cavity and pharynx; Bones, joints and articular cartilage of other and unspecified sites; Other and unspecified parts of tongue; Floor of mouth; Tonsil; Other and unspecified parts of mouth; Oropharynx; Larynx | 1 | 528 | 0.19% | 0.03% to 1.06% |
| p.S288* | TCGA-LUAD | Cystic, Mucinous and Serous Neoplasms; Ductal and Lobular Neoplasms; Acinar Cell Neoplasms; Adenomas and Adenocarcinomas; Bronchus and lung | 1 | 573 | 0.17% | 0.03% to 0.98% |
| p.S288* | TCGA-OV | Not Reported; Cystic, Mucinous and Serous Neoplasms; Ovary; Retroperitoneum and peritoneum | 1 | 603 | 0.17% | 0.03% to 0.93% |
Literature-extracted relations (61)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Quinacrine | Chemical | associate |
Quinacrine Has Preferential Anticancer Effects on Mesothelioma Cells With Inactivating NF2 Mutations. | 2021 |
| Sirolimus | Chemical | negative_correlate |
mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. | 2014 |
| BEVACIZUMAB | Chemical | negative_correlate |
Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. | 2013 |
| Ranolazine | Chemical | negative_correlate |
Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36). | 2010 |
| BEVACIZUMAB | Chemical | negative_correlate |
Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. | 2010 |
Showing 5 of 61 relation assertions.
Organizations publishing (187)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Mass General Brigham | Hospital | 26 | 2009 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 12 | 2012 to 2026 |
| Harvard Medical School | Academic | 10 | 2012 to 2023 |
| Government of the United States of America | Government | 9 | 2014 to 2024 |
| The University of Texas System | Academic | 7 | 2015 to 2022 |
Showing 5 of 187 organizations.
Where NF2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
377 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.